其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Imatinib CAS Registry Number: 152459-95-5 伊马替尼

CAS Name: 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
Additional Names: N-[5-[4-(4-methylpiperazinomethyl)benzoylamido]-2-methylpheny...
Literature References: Tyrosine kinase inhibitor; highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Also shown to inhibit the transmembrane receptor KIT and platelet-derived growth factor (PDGF) receptors. Prepn: J. Zimmermann, EP 564409; idem, US 5521184 (1993, 1996 both to Ciba-Geigy); idem et al., Bioorg. Med. Chem. Lett. 7, 187 (1997). Structural mechanism of ABL specificity: T. Schindler et al., Science 289, 1938 (2000). Activity vs KIT and PDGF receptor kinases: E. Buchdunger et al., J. Pharmacol. Exp. Ther. 295, 139 (2000). Clinical trial in CML: H. Kantarjian et al., N. Engl. J. Med. 346, 645 (2002); in gastrointestinal stromal tumors related to KIT: G. D. Demetri et al., ibid. 347, 472 (2002). Review of clinical experience: D. G. Savage, K. H. Antman, ibid. 346, 683-693 (2002); and pharmacology: V. K. Pindolia et al., Pharmacotherapy 22, 1249-1265 (2002); and development of therapeutic target: B. J. Druker, Adv. Cancer Res. 91, 1-30 (2004).

Idebenone CAS Registry Number: 58186-27-9 艾地苯醌

CAS Name: 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
Additional Names: 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone; 2,3-dimethoxy-5-methyl-6-(10'-hy...
Literature References: Ubiquinone derivative with protective effects against cerebral ischemia. Prepn: H. Morimoto et al., DE 2519730; eidem, US 4271083 (1975, 1981 both to Takeda); K. Okamoto et al., Chem. Pharm. Bull. 30, 2797 (1982); C.-A. Yu, L. Yu, Biochemistry 21, 4096 (1982). Effect on ischemia-induced amnesia in rats: N. Yamazaki et al., Jpn. J. Pharmacol. 36, 349 (1984). Metabolism in animals: T. Kobayashi et al., J. Pharmacobio-Dyn. 8, 448 (1985). Disposition: H. Torii et al., ibid. 457. Pharmacokinetics and tolerance in humans: M. F. Barkworth et al., Arzneim.-Forsch. 35, 1704 (1985). Series of articles on pharmacology and clinical studies: Arch. Gerontol. Geriatr. 8, 193-366 (1989). Review of chemistry, toxicology and pharmacology: I. Zs-Nagy, Arch. Gerontol. Geriatr. 11, 177-186 (1990).

Clevidipine CAS Registry Number: 167221-71-8 丁酸氯维地平

CAS Name: 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl (1-oxybutoxy)methyl ester
Additional Names: butyroxymethyl methyl 4-(2',3'-dichlorophenyl)-2,6-dim...
Literature References: Ultrashort-acting dihydropyridine calcium channel antagonist. Prepn: K. H. Andersson et al., WO 9512578; eidem, US 5856346 (1995, 1999 both to Astra). Improved prepn: A. Mattson et al., WO 0031035 (2000 to AstraZeneca). Capillary GC/MS determn in whole blood: C. Fakt, H. Stenhoff, J. Chromatogr. B 723, 211 (1999). Clinical pharmacokinetics: H. Ericsson et al., Br. J. Clin. Pharmacol. 47, 531 (1999); and pulmonary extraction during cardiopulmonary bypass: A. Vuylsteke et al., Br. J. Anaesth. 85, 683 (2000). Clinical evaluation in hypertension in postoperative cardiac surgical patients: N. Kieler-Jensen et al., Acta Anaesthesiol. Scand. 44, 186 (2000); J. M. Bailey et al., Anesthesiology 96, 1086 (2002). Review of pharmacology and clinical development: M. Nordlander et al., Cardiovasc. Drug Rev. 22, 227-250 (2004).

Ferumoxtran 10 CAS Registry Number: 189047-99-2

Trademarks: Combidex (Advanced Magnetics); Sinerem (Guerbet)
Literature References: Ultrasmall superparamagnetic iron oxide (USPIO) magnetite nanoparticles covered with low molecular weight dextran T-10; designed for use as an MRI imaging agent to detect metastatic cancer in lymph nodes. Prepn: E. V. Groman et al.,WO 8800060; S. Palmacci, L. Josephson, US 5262176 (1988, 1993 both to Advanced Magnetics). Physical and chemical properties: C. W. Jung, P. Jacobs, Magn. Reson. Imaging 13, 661 (1995); surface properties: C. W. Jung, ibid. 675. Biodistribution study: H. H. Bengele et al., ibid. 12, 433 (1994). Clinical studies of diagnostic use: Y. Anai et al., Radiology 228, 777 (2003); A. G. Rockall et al., J. Clin. Oncol. 23, 2813 (2005). Review of clinical experience: M. G. Harisinghani et al., RadioGraphics 24, 867-878 (2004); of pharmacology and preclinical studies: P. Bourrinet et al., Invest. Radiol. 41, 313 2006.

Suprasterol II CAS Registry Number: 562-71-0

CAS Name: (2a,7a,8R,19a,22E)-7,19:8,19-Dicyclo-9,10-secoergosta-5(10),22-dien-2-ol
Percent Composition: C 84.78%, H 11.18%, O 4.03%
Literature References: Ultraviolet irradiation product of vitamin D2. Isoln: Windaus et al., Ann. 483, 17 (1930). Structure and stereochemistry: Dauben, Baumann, Tetrahedron Lett. 1961, 565. Crystal structure: C. P. Saunderson et al., ibid. 573. Improved isoln and spectral data: T. Kobayashi et al., J. Nutr. Sci. Vitaminol. 23, 291 (1977).

Bupropion CAS Registry Number: 34911-55-2 安非他酮

CAS Name: 1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone
Additional Names: (±)-2-(tert-butylamino)-3'-chloropropiophenone; m-chloro-a-(tert-butylamino)propiophenone; amfebutam...
Literature References: Unicyclic aminoketone with noradrenergic and dopaminergic activity. Prepn: N. B. Mehta, D. A. Yeowell, DE 2059618 (1971 to Wellcome Found.); N. B. Mehta, US 3819706 (1974 to Burroughs Wellcome). Pharmacology: F. Soroko et al., J. Pharm. Pharmacol. 29, 767 (1977). Preclinical toxicology: W. E. Tucker, J. Clin. Psychiatry 44, 60-62 (1983). Pharmacokinetics in smokers: P.-H. Hsyu et al., J. Clin. Pharmacol. 37, 737 (1997). Clinical trial in attention deficit disorder with hyperactivity: C. K. Conners et al., J. Am. Acad. Child Adolesc. Psychiatry 34, 1314 (1996); in smoking cessation: D. E. Jorenby et al., N. Engl. J. Med. 340, 685 (1999). Review of pharmacology and clinical efficacy in depression: S. G. Bryant et al., Clin. Pharm. 2, 525-537 (1983); of mechanism of action studies: J. A. Ascher et al., J. Clin. Psychiatry 56, 395-401 (1995); of clinical use in smoking cessation: R. West, Expert Opin. Pharmacother. 4, 533-540 (2003).

Cellobiose CAS Registry Number: 528-50-7 D(+)-纤维二糖

CAS Name: 4-O-b-D-Glucopyranosyl-D-glucose
Additional Names: b-cellobiose; cellose; 4-(b-D-glucosido)-D-glucose
Percent Composition: C 42.11%, H 6.48%, O 51.41%
Literature References: Unit of cellulose and lichenin. Does not occur free in nature, or as glucoside. Prepn from cotton: Braun, Org. Synth. coll. vol. II, 122, 124 (1943). Prepn from cell-free enzymatic hydrolyzate of cellulose: Whistler, Smart, J. Am. Chem. Soc. 75, 1916 (1953). Structure: Haworth, Hirst, J. Chem. Soc. 119, 193 (1923); Charlton et al., ibid. 1926, 89; Zemplén, Ber. 59, 1254 (1926); Haworth et al., J. Chem. Soc. 1927, 2809; Peterson, Spencer, J. Am. Chem. Soc. 49, 2822 (1927); Helferich et al., Ber. 63, 992 (1930); Hess, Dziengel, ibid. 68, 1594 (1935); Hassid, Ballou in The Carbohydrates, W. Pigman, Ed. (Academic Press, New York, 1957) p 490. Synthesis: Haskins et al., J. Am. Chem. Soc. 64, 1289 (1942). Review: Pazur in The Carbohydrates vol. 2A, W. Pigman et al., Eds. (Academic Press, New York, 2nd ed., 1970) pp 109-110; R. G. Edwards, Dev. Food Carbohydr. 2, 229-273 (1980).

Koser's Reagent CAS Registry Number: 27126-76-7 羟基(甲苯磺酰氧代)碘苯

CAS Name: Hydroxy(4-methylbenzenesulfonato-kO)phenyliodine
Additional Names: [hydroxy(tosyloxy)iodo]benzene; HTIB; phenyliodoso hydroxide tosylate; phenylhydroxytosyloxyiodine
Percent Compos...
Literature References: Unsymmetrical aryl l3-iodane. Prepn: O. Y. Neiland, B. Y. Karele, J. Org. Chem. USSR 6, 889 (1970). Solid state structure determn by single-crystal x-ray analysis: G. F. Koser et al., J. Org. Chem. 41, 3609 (1976). Review of use in organic synthesis: R. M. Moriarty et al., Synlett 1990, 365-383; of chemistry: G. F. Koser, Aldrichim. Acta 34, 89-102 (2001).

Maddrell's Salt CAS Registry Number: 10361-03-2 偏磷酸钠

Additional Names: Polymeric sodium metaphosphate
Literature References: Upon heating NaH2PO4 or NaNH4HPO4 to 250° and then slowly to 350°, first Na2H2P2O7 and then the insol Maddrell's salt is obtained, which is stable to about 500°; at 505° it changes to sodium trimetaphosphate, and above 607° to sodium hexametaphosphate. According to Maddrell, Ann. 61, 63 (1847) the salt may be prepd by heating two parts NaNO3 with one part H3PO4. An improved procedure is described by v. Knorre, Z. Anorg. Chem. 24, 397 (1900). Structure: Jost, Acta Crystallogr. 16, 428 (1963). Reviews: see Sodium Metaphosphate.

Acetohydroxamic Acid CAS Registry Number: 546-88-3 乙酰氧肟酸

CAS Name: N-Hydroxyacetamide
Additional Names: N-acetylhydroxylamine; acetic acid oxime; AHA
Trademarks: Lithostat (Mission Pharmacal)
Percent Composition: C 32.00%, H 6.71%, N 18.66%, O ...
Literature References: Urease inhibitor. Prepn: A. Miolati, Ber. 25, 699 (1892); W. M. Wise, W. W. Brandt, J. Am. Chem. Soc. 77, 1058 (1955); H. A. Staab et al., Ber. 95, 1275 (1962); G. Sosnovsky, J. A. Krogh, Synthesis 1980, 654. Inhibition of urease activity: K. Kobashi et al., Biochim. Biophys. Acta 65, 380 (1962); W. N. Fishbein et al., Nature 208, 46 (1965); W. N. Fishbein, P. P. Carbone, J. Biol. Chem. 240, 2407 (1965); D. P. Griffith et al., Invest. Urol. 11, 234 (1973). Metabolism: E. Wolpert et al., Proc. Soc. Exp. Biol. Med. 136, 592 (1971); W. N. Fishbein et al., J. Pharmacol. Exp. Ther. 186, 173 (1973). Pharmacokinetics: S. Feldman et al., Invest. Urol. 15, 498 (1978). Clinical studies in treatment of kidney stones: D. B. Griffith et al., J. Urol. 119, 9 (1978); A. Martelli et al., Urology 17, 320 (1981).